The device, which directs a liquid by mimicking squids’ high-pressure jets, could provide alternative delivery methods for injectable drugs.

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market ...

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution ...

Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the ...

This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.

Cipla received approval from India's Central Drugs Standard Control Organisation to distribute and market Afrezza inhalation ...

In a report released today, James Vane from Jefferies maintained a Buy rating on Gerresheimer (0NTI – Research Report), with a price target of ...

Understanding insulin pumps: key components, benefits, and advancements in technology for effective diabetes management and ...